Heather Raymon
Net worth: 1 M $ as of 2026-05-30
Net worth: 1 M $ as of 2026-05-30
Heather Raymon currently works at Artiva Biotherapeutics, Inc., as Senior VP-Research & Early Development from 2023.
Dr. Raymon also formerly worked at Bristol Myers Squibb Co., as Executive Director-Early Development Program and Celgene Corp., as Senior Director & Head-Pharmacology.
Dr. Raymon received her undergraduate degree from State University of New York at Albany and doctorate degree from the University of California, Irvine.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-05-18 | 148,228 ( 0.31% ) | 1 M $ | 2026-05-30 |
| Companies | Position | Start |
|---|---|---|
| ARTIVA BIOTHERAPEUTICS, INC. | Corporate Officer/Principal | 2020-09-30 |
| Companies | Position | End |
|---|---|---|
| CELGENE | Corporate Officer/Principal | - |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 5 |
|---|---|
Bristol Myers Squibb Co.
Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
Celgene Corp.
Celgene Corp. BiotechnologyHealth Technology Develops cancer and immunology drugs | Health Technology |
State University of New York at Albany
State University of New York at Albany Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California, Irvine
University of California, Irvine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which develops natural killer cell-based therapies for patients suffering from autoimmune diseases and cancers | Health Technology |
Select your edition
All financial news and data tailored to specific country editions